(Q34162069)

English

Requiring an amyloid‐β1‐42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials

scientific article published on September 1, 2010

In more languages
default values for all languages
No label defined

No description defined

Statements

Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials (English)
Requiring an amyloid‐β1‐42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit